Core Viewpoint - The company, 开拓药业-B (09939), announced that its chairman and CEO, Dr. Tong Youzhi, has increased his stake in the company by purchasing 4.7 million shares for approximately HKD 10.82 million, reflecting confidence in the company's future growth and commercialization potential [1]. Group 1: Share Purchase Details - Dr. Tong acquired the shares through his wholly-owned company, KT International Investment Limited, in the open market at an average price of HKD 2.30 per share, with a price range between HKD 1.89 and HKD 2.81 [1]. - This purchase represents approximately 0.9425% of the company's total issued share capital as of the announcement date [1]. Group 2: Management Confidence - Dr. Tong expressed strong confidence in the overall development prospects and commercialization transformation of the company [1]. - The board believes that this share purchase demonstrates Dr. Tong's firm belief in the clinical progress and growth potential of the company's innovative topical drugs, particularly in the hair loss treatment pipeline [1]. - The company maintains sufficient public float after this share purchase, indicating a stable shareholder structure [1].

Core Viewpoint - The company, 开拓药业-B (09939), announced that its chairman and CEO, Dr. 童友之, has increased his stake in the company by purchasing 4.7 million shares for approximately HKD 10.82 million, reflecting confidence in the company's future growth and commercialization potential [1] Group 1: Share Purchase Details - Dr. 童友之 acquired 4.7 million shares at an average price of HKD 2.30 per share, with a price range between HKD 1.89 and HKD 2.81 [1] - This purchase represents approximately 0.9425% of the company's total issued share capital as of the announcement date [1] - The acquisition was made through Dr. 童友之's wholly-owned company, KT International Investment Limited, using personal funds [1] Group 2: Future Outlook and Confidence - Dr. 童友之 expressed strong confidence in the overall development prospects and commercialization transformation of the company [1] - The board of directors believes that this share purchase demonstrates Dr. 童友之's firm confidence in the clinical progress and commercialization potential of the company's innovative topical drugs, particularly in the hair loss treatment pipeline [1] - The company maintains sufficient public float after this share purchase, and Dr. 童友之 does not rule out the possibility of further increasing his stake after the quiet period ends on March 26, 2026 [1]